alexa Trend in the use of intra-uterine contraceptive device (IUCD ,TCU 380A), in Enugu, Nigeria.


Journal of Womens Health Care

Author(s): Ezegwui HU, NwoguIkojo EE, Ikeako LC, Nweze S

Abstract Share this page

Abstract OBJECTIVE: To estimate the acceptance rate and trend of Intrauterine Contraceptive Device (IUCD) use in Enugu, Nigeria PATIENTS AND METHODS: A review of all new acceptors of intrauterine contraceptive device (IUCD) over a nine year period (1999-2007). RESULTS: A total of 133,375 clients were seen at the UNTH family planning clinic between 1999 and 2007. Out of 6,947 users of IUCD, during the period, 1,659 were new acceptors. The IUCD acceptance rate was 5.21\%. Majority of the clients (29.7\%) were aged 40 years and above. Eight hundred and forty seven (51.4\%) had attained post secondary education. Majority of the clients (99.4\%) were married . Twenty-six percent (26.0\%) had completed their desired family size. Majority 1,359 (82.4\%) did not use any method contraception prior to IUCD insertion. The commonest complication was menorrhagia (5.8\%) and this was responsible for removal in 3.0\% of cases. Eight (0.5\%) and nine (0.6\%) requested for removal for fear of causing cancer and migration to the brain or heart respectively. Two (0.1\%) became pregnant while having the IUCD in-situ. Majority of the clients (50.5\%) had the knowledge of lUCD through friends. CONCLUSION: This study has shown that IUCD (TCU 380A) is both safe and effective in Enugu, Nigeria. Its use is for both child spacing and limiting family size.
This article was published in Niger J Med and referenced in Journal of Womens Health Care

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version